Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...

Red blood cells in an artery with cholesterol

In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

BioWorld

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...

Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty

BioWorld

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...